Rekvina Laboratories' independent directors recommended an open offer at ₹10 per share, calling it fair. However, they cautioned shareholders about the significant difference from the market price of ₹37.45, advising due diligence.
Rekvina Laboratories Open Offer: Independent Directors Recommend Fair Value Despite Price Gap
Rekvina Laboratories is currently subject to an open offer where acquirers Surbhit Mukesh Shah, Amit Mukesh Shah, and DhruvalDhruvalkumar Patel propose to acquire 28,90,100 equity shares, representing 26% of the expanded share capital. The offer price is set at ₹10 per share, totaling ₹2.89 crore.
What just happened
An Open Offer was made by Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel to acquire 28,90,100 shares of Rekvina Laboratories at ₹10 per share.
The Committee of Independent Directors (IDC) reviewed the offer and has recommended it as fair and reasonable, adhering to SEBI regulations.
Why this matters
While the IDC found the offer compliant, a significant disparity exists between the offer price (₹10) and the market price (₹37.45 as of June 23, 2026). This highlights a potential concern for shareholders regarding the valuation.
The backstory
The acquisition is part of a strategic plan to integrate operations with Radiant Parenterals Limited. The stated goals include expanding market presence, consolidating operations, leveraging efficiencies, and increasing market share.
What changes now
The IDC's recommendation supports the offer's regulatory compliance. However, the explicit caution to shareholders means they must decide independently whether to tender their shares, weighing the offer against the higher market price.
Risks to watch
The primary risk for shareholders is tendering shares at ₹10 when the market values them at ₹37.45. Independent evaluation is crucial.
Peer comparison
(No direct peer comparison data was provided in the filing.)
Context metrics (time-bound)
- Offer Price: ₹10 per share
- Market Price (June 23, 2026): ₹37.45 per share
- Offer Size: 28,90,100 Shares (26% of Expanded Share Capital)
- Total Consideration: ₹2.89 crore
What to track next
Shareholders should closely monitor their decision-making process and the subsequent stock performance of Rekvina Laboratories post-offer.
Reader Takeaway: Independent directors found the offer fair, but the price gap prompts caution for shareholders on tendering shares.